Search Results - "González Larriba, J.L"

2638 Effectiveness of 2nd-line and subsequent therapies after pazopanib (Paz) in patients (pt) with metastatic renal cell carcinoma (mRCC): Final results of the SPAZO study (SOGUG) by Arija, J.A. Arranz, Pérez-Valderrama, B, González-Larriba, J.L, Rodríguez Sánchez, A, Chirivella, I, Pinto, A, Marrero, R.D. García, Rubio, G, García, J.M. Jurado, Borrega, P, Quintela, M. Lázaro, Castellano, D.E, Rodríguez, C. Suárez, García, J.A. Meana, Lambea-Sorrosal, J.J, Gajate, P, Fita, M.J. Juan, Puertas, J.L, Domínguez, R. García, Guzmán, J.C. Villa

Get full text

Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non–Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial by ALBEROLA, V, CAMPS, C, GONZALEZ-LARRIBA, J. L, DIZ, P, CARDENAL, F, ARTAL, A, CARRATO, A, MORALES, S, SANCHEZ, J. J, DE LAS PENAS, R, FELIP, E, LOPEZ-VIVANCO, G, PROVENCIO, M, ISLA, D, ROSELL, R, VADELL, C, BOVER, I, RUIZ-CASADO, A, AZAGRA, P, JIMENEZ, U

“…To compare the survival benefit obtained with cisplatin plus gemcitabine, a cisplatin-based triplet, and nonplatinum sequential doublets in advanced…”
Get full text

Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours by LÓPEZ-POUSA, A., RIFÀ, J., CASAS DE TEJERINA, A., GONZÁLEZ-LARRIBA, J.L., IGLESIAS, C., GASQUET, J.A., CARRATO, A.

“…LÓPEZ‐POUSA A., RIFÀ J., CASAS DE TEJERINA A., GONZÁLEZ‐LARRIBA J.L., IGLESIAS C., GASQUET J.A. & CARRATO A. (2010) European Journal of Cancer Care Risk…”
Get full text

Phase I-II Study of Paclitaxel, Cisplatin, and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium by BELLMUNT, J, GUILLEM, V, BASTUS, R, CLIMENT, M. A, DE LA CRUZ, J. J, ALBANELL, J, BANUS, J. M, GALLARDO, E, DIAZ-RUBIO, E, CORTES-FUNES, H, BASELGA, J, PAZ-ARES, L, GONZALEZ-LARRIBA, J. L, CARIES, J, BATISTE-ALENTORN, E, SAENZ, A, LOPEZ-BREA, M, FONT, A, NOGUE, M

“…PURPOSE: To determine the maximum-tolerated dose and the antitumor activity of a combination of paclitaxel, cisplatin, and gemcitabine in advanced…”
Get full text

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results by Paz-Ares, L., Goto, Y., Lim, W.D.T., Halmos, B., Cho, B.C., Dols, M. Cobo, Gonzalez-Larriba, J.L., Zhou, C., Demedts, I., Atmaca, A., Baka, S., Mookerjee, B.P., Portella, S., Zhu, Z., Dharan, B., Reck, M.

Get full text

Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study by AVRIL, M. F, AAMDAL, S, PORTA, V. Guillem, FRA, J, BONNETERRE, J, SAÏAG, P, KAMANABROU, D, PEHAMBERGER, H, SUFLIARSKY, J, GONZALEZ LARRIBA, J. L, SCHERRER, A, MENU, Y, GROB, J. J, HAUSCHILD, A, MOHR, P, BONERANDI, J. J, WEICHENTHAL, M, NEUBER, K, BIEBER, T, GILDE, K

“…To compare fotemustine and dacarbazine (DTIC) in terms of overall response rate (ORR) as primary end-point and overall survival, duration of responses, time to…”
Get full text

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients by Cortes-Funes, H., Gomez, C., Rosell, R., Valero, P., Garcia-Giron, C., Velasco, A., Izquierdo, A., Diz, P., Camps, C., Castellanos, D., Alberola, V., Cardenal, F., Gonzalez-Larriba, J. L., Vieitez, J. M., Maeztu, I., Sanchez, J. J., Queralt, C., Mayo, C., Mendez, P., Moran, T., Taron, M.

“…Background:: North American and Japanese non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) activation via tyrosine…”
Get full text

Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer by Bellmunt, J., Guillem, V., Paz-Ares, L., González-Larriba, J.L., Carles, J., Albanell, J., Tabernero, J.M., Cortés-Funes, H., Baselga, J.

“…Transitional cell carcinoma (TCC) of the urothelium is a highly chemosensitive tumour. Combination chemotherapy can provide both palliation and a modest…”
Get full text

1128 POSTER Risk assessment model for chemotherapy-induced anemia in patients with solid tumours: DELFOS Study by López Pousa, A, Rifá, J, Casas Fernández de Tejerina, A, González Larriba, J.L, Mercadal, J, Gasquet, J.A, Carrrato, A

Get full text

6567 POSTER Clinical and economic impact of febrile neutropenia management of lung cancer patients in clinical practice in Spain by Viñolas, N, Gúrpide, A, Frau, A, González Larriba, J.L, Lamas, M.J, Alvarez, F, Layola, M, Gasquet, J.A

Get full text

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity by Bellmunt, J., González-Larriba, J.L., Prior, C., Maroto, P., Carles, J., Castellano, D., Mellado, B., Gallardo, E., Perez-Gracia, J.L., Aguilar, G., Villanueva, X., Albanell, J., Calvo, A.

“…A strong rationale supports the role of antiangiogenic drugs in urothelial cancer. This trial was designed to assess the activity of sunitinib as first-line…”
Get full text

6534 POSTER Elevated levels of thioredoxin (Trx) in serum correlate with poor outcome in docetaxel (doc)/cisplatin (cis)-treated stage IV non-small-cell lung cancer (NSCLC) patients (pts) by Molina, M.A, Camps, C, DelasPeñas, R, Alonso, G, Lopez-Vivanco, G, Provencio, M, González-Larriba, J.L, Salazar, F, Sánchez, J.J, Rosell, R

Get full text

Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group by Remon, J., Nadal, E., Dómine, M., Ruffinelli, J., García, Y., Pardo, J.C., López, R., Cilleruelo, A., García-Campelo, R., Martín, P., Juan, O., González-Larriba, J.L., Provencio, M., Olmedo, E., Ponce, S., Cumplido, D., Barenys, C., Majem, M., Massutti, B., Rodriguez-Abreu, D., Porta, R., Sala, M.A., Martinez-Kareaga, M., Lianes, P., Reguart, N.

“…•Epidemiological report of mesothelioma treatment patterns and outcomes in Spain.•Despite multimodal intervention, outcomes remain poor (1-year OS of 53.2…”
Get full text

A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN) by Bellmunt, J., Kerst, J.M., Vázquez, F., Morales-Barrera, R., Grande, E., Medina, A., González Graguera, M.B., Rubio, G., Anido, U., Fernández Calvo, O., González-Billalabeitia, E., Van den Eertwegh, A.J.M., Pujol, E., Perez-Gracia, J.L., González Larriba, J.L., Collado, R., Los, M., Maciá, S., De Wit, R.

“…Despite the advent of immunotherapy in urothelial cancer, there is still a need to find effective cytotoxic agents beyond first and second lines. Vinflunine is…”
Get full text

IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC by Reck, M., Wehler, T., Orlandi, F., Nogami, N., Barone, C., Moro-Sibilot, D., Shtivelband, M., González Larriba, J.L., Rothenstein, J., Frueh, M., Shankar, G., Lee, A., Deng, Y., Patel, H., Kelsch, C., Lin, W., Socinski, M.A.

Get full text

9030 POSTER An Expression Profile Classifies Early Stage Non-small Cell Lung Cancer Into Two Groups With Good and Poor Disease-free Survival Rates by Sanz, J, Hernandez, S, Romera, A, Ferrer, M, Perez-Villamil, B, Jarabo, J.R, Gomez, A, Hernando, F, Puente, J, Gonzalez-Larriba, J.L

Get full text

Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice by Zugazagoitia, J, Puente, J, González-Larriba, J L, Manzano, A, Sotelo, M, Hernández, S, Sanz, J, Pérez, P, Díaz-Rubio, E

“…Erlotinib and chemotherapy have shown similar efficacy for pretreated non-small cell lung cancer (NSCLC) patients, but none of the large studies have selected…”
Get more information

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies††These studies have previously been presented in part at the ASCO 2013 Annual Meeting, the ESMO-ECCO 2013 Annual Meeting and the IASLC 2013 World Conference on Lung Cancer by Moran, T., Wei, J., Qian, X., Domine, M., Zou, Z., Wang, L., Provencio, M., Yu, L., Song, Y., Vergnenegre, A., Lu, H., Lopez-Vivanco, G., Majem, M., Chen, X., Karachaliou, N., Sala, M.A., Wu, Q., Isla, D., Baize, N., Zhang, F., Garde, J., Germonpre, P., Drozdowskyj, A., Sanchez, J.J., Liu, B., Rosell, R., De Grève, J., Germonpré, P., Chen, H., Chen, X., Gao, Y., Hu, W., Kong, W., Li, L., Li, X., Lu, H., Qian, X., Ren, W., Song, Y., Wei, J., Xu, X., Yang, J., Yang, M., Yue, X., Zhang, J., Zou, Z., Bombaron, P., Dansin, E., Fraboulet, G., Hominal, S., Kahlout, S., Lecaer, H., Lena, H., Monnet, I., Oliviero, G., Schoot, R., Vergnènegre, A., Berchem, G., Al Husaini, H., Aparisi, F., Arriola, E., Bernabé, R., Bosch-Barrera, J., Bover, I., Calvo de Juan, V., Cobo, M., De las Peñas, R., García-Girón, C., García-Gómez, R., Garcia-Sevila, R., Garde, J., Gasco, A., González-Larriba, J.L., Hernando-Polo, S., Jantus, E., Isla, D., Jiménez, B., Lianes, P., López-Martín, A., Macias, J.A., Marti-Ciriquian, J.L., Morán, T., Moreno, M.A., Pallares, C., Porta, R., Reguart, N., Rosell, R., Rosillo, F., Sala, M.A., Sanchez, J.M., Trigo, J.M., Viteri, S., Mate, J.L., Perez-Cano, M., Ramirez, J.L., Sanchez-Rodriguez, B., Ocaña, J., Pereira, E., Shao, J., Sun, X.

“…In a Spanish Lung Cancer Group (SLCG) phase II trial, the combination of BRCA1 and receptor-associated protein 80 (RAP80) expression was significantly…”
Get full text

PO-412 Effectiveness and safety of anti-PD1 (Nivolumab) as second line treatment of advanced non-small cell lung cancer (NSCLC) elderly and heavy smokers patients (PTS) with unknown PD-1 status by Fusco, JP, Acosta, D, Pérez-Carrión, R, Castillo, M Del, Caviedes, E, Garzón, C, Ramirez, N, Fiorini, A, González-Larriba, JL

“…IntroductionPD1 (Programmed cell death) is a receptor expressed on activated T cells, produces down regulation of T cell when interacts with ligands PDL1-PDL2…”
Get full text

Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population by Castellano, D., del Muro, X. Garcia, Pérez-Gracia, J. L., González-Larriba, J. L., Abrio, M. V., Ruiz, M. A., Pardo, A., Guzmán, C., Cerezo, S. Díaz, Grande, E.

“…Background: The purpose of this study is to evaluate the impact on the health-related quality of life (HRQoL) of sunitinib versus interferon-alpha (IFN-α)…”
Get full text